183 related articles for article (PubMed ID: 21909139)
1. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
2. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
3. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
Granados ML; Hudson LG; Samudio-Ruiz SL
PLoS One; 2015; 10(9):e0136893. PubMed ID: 26351843
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
Eckstein N; Servan K; Girard L; Cai D; von Jonquieres G; Jaehde U; Kassack MU; Gazdar AF; Minna JD; Royer HD
J Biol Chem; 2008 Jan; 283(2):739-50. PubMed ID: 17942395
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.
Cole C; Lau S; Backen A; Clamp A; Rushton G; Dive C; Hodgkinson C; McVey R; Kitchener H; Jayson GC
Cancer Biol Ther; 2010 Sep; 10(5):495-504. PubMed ID: 20595807
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway.
Rui X; Pan HF; Shao SL; Xu XM
BMC Complement Altern Med; 2017 Aug; 17(1):378. PubMed ID: 28764703
[TBL] [Abstract][Full Text] [Related]
7. Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
Nakamura H; Nagasaka K; Kawana K; Taguchi A; Uehara Y; Yoshida M; Sato M; Nishida H; Fujimoto A; Inoue T; Adachi K; Nagamatsu T; Arimoto T; Oda K; Osuga Y; Fujii T
BMC Cancer; 2016 Nov; 16(1):897. PubMed ID: 27855669
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer.
Standing D; Dandawate P; Gunewardena S; Covarrubias-Zambrano O; Roby KF; Khabele D; Jewell A; Tawfik O; Bossmann SH; Godwin AK; Weir SJ; Jensen RA; Anant S
Cell Death Dis; 2024 May; 15(5):362. PubMed ID: 38796478
[TBL] [Abstract][Full Text] [Related]
9. 3'-Hydroxypterostilbene Potently Suppresses Tumor Growth via Inhibiting the Activation of the JAK2/STAT3 Pathway in Ovarian Clear Cell Carcinoma.
Koh YC; Huang WZ; Nagabhushanam K; Ho CT; Pan MH
Mol Nutr Food Res; 2024 Jan; 68(1):e2300108. PubMed ID: 37876143
[TBL] [Abstract][Full Text] [Related]
10. NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.
Zhou Y; Zhu Y; Fan X; Zhang C; Wang Y; Zhang L; Zhang H; Wen T; Zhang K; Huo X; Jiang X; Bu Y; Zhang Y
Oncotarget; 2017 May; 8(20):33110-33121. PubMed ID: 28416770
[TBL] [Abstract][Full Text] [Related]
11. Radix Tetrastigma Hemsleyani Flavone represses cutaneous squamous cell carcinoma via Janus kinase/signal transducer and activator of transcription 3 pathway inactivation.
Peng J; Luo X; Wang T; Yue C; Duan M; Wu C
Cytokine; 2024 Mar; 175():156480. PubMed ID: 38232644
[TBL] [Abstract][Full Text] [Related]
12. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line.
Omidi F; Shahbazi S; Reiisi S; Azhdari S; Karimzadeh MR
Toxicol In Vitro; 2023 Dec; 93():105687. PubMed ID: 37659683
[TBL] [Abstract][Full Text] [Related]
14. A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR.
Lau TS; Chan LK; Wong EC; Hui CW; Sneddon K; Cheung TH; Yim SF; Lee JH; Yeung CS; Chung TK; Kwong J
Oncogene; 2017 Jun; 36(25):3576-3587. PubMed ID: 28166193
[TBL] [Abstract][Full Text] [Related]
15. Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).
Zhang G; Hou S; Li S; Wang Y; Cui W
Int J Oncol; 2024 May; 64(5):. PubMed ID: 38488027
[TBL] [Abstract][Full Text] [Related]
16. Integrated transcriptomic and proteomic analysis reveals Guizhi-Fuling Wan inhibiting STAT3-EMT in ovarian cancer progression.
Ma Q; Chen F; Liu Y; Wu K; Bu Z; Qiu C; Neamati N; Lu T
Biomed Pharmacother; 2024 Jan; 170():116016. PubMed ID: 38128180
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
Kuan FC; Li JM; Huang YC; Chang SF; Shi CS
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139437
[TBL] [Abstract][Full Text] [Related]
18. Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma.
Kenchappa RS; Dovas A; Argenziano MG; Meyer CT; Stopfer LE; Banu MA; Pereira B; Griffith J; Mohammad A; Talele S; Haddock A; Zarco N; Elmquist W; White F; Quaranta V; Sims P; Canoll P; Rosenfeld SS
Cell Rep; 2022 Jun; 39(12):110991. PubMed ID: 35732128
[TBL] [Abstract][Full Text] [Related]
19. KIF22 promotes the proliferation and glycolysis of melanoma by activating EGFR/STAT3 signaling.
Zhong Z; Zhong H
Clinics (Sao Paulo); 2023; 78():100307. PubMed ID: 37944197
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between KDEL receptor and EGF receptor mediates cell proliferation and migration via STAT3 signaling.
Jia J; Zhu L; Yue X; Tang S; Jing S; Tan C; Du Y; Gao J; Lee I; Qian Y
Cell Commun Signal; 2024 Feb; 22(1):140. PubMed ID: 38378560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
